Lobbying Information
Subject Matters
- Economic Development
- Health
- Industry
- Intellectual Property
- International Development
- International Trade
- Regional Development
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Health Canada regarding the modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals.
- Industry Canada regarding export provisions of the Patent Act (pharmaceuticals)
- Industry Canada with respect to the Patent Act as it pertains to pharmaceuticals.
- Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property
Policies or Program
- Health Canada regarding the development and implementation of an approval pathway for Subsequent Entry Biologics (SEBs)
- Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Product Directorate to meet performance targets for the review of generic drug submissions.
- Health Canada, Industry Canada and International Trade to address fundamental flaws with respect to Canada's Access to Medicines Regimes
- Health Canada, Industry Canada, and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
- Industry Canada's science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
Regulation
- Canadian Generic Pharmaceutical Association's ("CGPA") legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to Data Exclusivity.
- Industry Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Canada Revenue Agency (CRA)
-
Canadian Heritage (PCH)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Industry Canada
-
Justice Canada (JC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Solicitor General Canada (SGC)
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Pharmascience Inc. is a Canadian-owned pharmaceutical company specializing in the manufacturing and distribution of generic, innovative, and consumer brand pharmaceutical products in Canada
Responsible officer name and position during the period of this registration
David Goodman,
Chief Executive Officer
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
6111 Royalmount avenue, suite 100
Montreal, QC H4P 2T4
Canada
Telephone number:
514-340-9800
Fax number:
514-342-3654
Parent Company Information
- Joddes Limited
-
6111 Royalmount Avenue, suite 100
Montreal, QC H4P 2T4
Canada
Subsidiary Beneficiary Information
Pharmascience Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Pierre Gaudreault,
General Manager, Pharmascience Canada |
No public offices held
- David Goodman,
Chief Executive Officer |
No public offices held
- Morris Goodman,
Chairman of the Board of Directors |
No public offices held
- Larry MacGirr,
President and COO |
No public offices held
- Leonard Neirinck,
Senior Vice President Scientific Affairs |
No public offices held
- Josée Thérien,
Director, Market Access |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
No lobbyists added
